Arbutus Biopharma Corporation
ABUS
$4.31
-$0.08-1.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.09% | 44.88% | 29.62% | -2.94% | 4.02% |
| Total Depreciation and Amortization | -73.70% | -51.28% | -29.81% | -4.91% | -1.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.94% | 82.75% | 83.48% | 189.63% | 74.21% |
| Change in Net Operating Assets | -254.29% | -982.66% | -686.52% | 160.50% | 84.48% |
| Cash from Operations | 38.88% | 36.97% | 17.41% | 24.36% | 24.54% |
| Capital Expenditure | -- | 10.42% | 32.81% | 91.18% | 81.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -55.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.22% | -4.49% | -47.57% | -51.47% | -55.31% |
| Cash from Investing | -32.11% | -4.44% | -47.61% | -50.64% | -54.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.00% | -89.88% | -88.15% | -12.44% | 69.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.00% | -89.88% | -88.15% | -12.44% | 69.66% |
| Foreign Exchange rate Adjustments | 128.57% | -900.00% | -400.00% | -500.00% | -296.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -282.40% | -165.93% | -171.30% | -338.43% | 323.67% |